Published in Mol Cancer Ther on June 22, 2010
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. BMC Cancer (2014) 0.81
A better TRAIL variant for tumor cell-specific targeting? - letter. Mol Cancer Ther (2010) 0.81
Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology. Sci Rep (2016) 0.79
Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members. Sci Signal (2014) 0.77
An optimized antibody-single-chain TRAIL fusion protein for cancer therapy. MAbs (2016) 0.77
Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane. Oncotarget (2016) 0.76
Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity. Cell Death Dis (2016) 0.75
A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route. Oncotarget (2016) 0.75
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 35.74
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature (2009) 7.24
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Cell death in development. Cell (1999) 6.01
Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer (2005) 5.65
Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer (2002) 4.76
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin (2005) 4.06
Tumor measurement in the nude mouse. J Surg Oncol (1986) 4.01
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol (2007) 2.49
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell (1999) 2.42
Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol (2007) 2.00
Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol (1999) 1.88
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem (2000) 1.27
Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem (2000) 1.15
Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci (2009) 1.14
2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity (1999) 1.14
TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther (2009) 1.13
Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer (2004) 1.09
Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol (2008) 1.07
New apoptosis drugs face critical test. Nat Biotechnol (2005) 1.01
ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol (2004) 1.00
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia (2009) 1.00
A multifunctional vector family for gene expression in mammalian cells. Gene (1994) 0.99
Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clin Cancer Res (2006) 0.96
In vivo correction of complement regulatory protein deficiency with an inhibitor targeting the red blood cell membrane. J Immunol (2005) 0.90
Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. J Mol Med (Berl) (2008) 0.86
Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA (2011) 7.10
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Cell death. N Engl J Med (2009) 4.75
The accordion severity grading system of surgical complications. Ann Surg (2009) 4.45
The sepsis seesaw: tilting toward immunosuppression. Nat Med (2009) 3.95
Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med (2013) 3.25
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg (2005) 3.04
Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature (2004) 2.98
Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? Ann Surg (2011) 2.87
Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol (2010) 2.81
The presence of hypothermia within 24 hours of sepsis diagnosis predicts persistent lymphopenia. Crit Care Med (2015) 2.81
Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. Ann Surg (2008) 2.80
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science (2002) 2.51
Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg (2008) 2.40
IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol (2010) 2.29
Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J Leukoc Biol (2009) 2.27
Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA (2002) 2.20
Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. Crit Care Med (2002) 2.20
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2012) 1.97
Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg (2012) 1.91
IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol (2009) 1.91
Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun (2011) 1.86
A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg (2010) 1.83
Sepsis from Pseudomonas aeruginosa pneumonia decreases intestinal proliferation and induces gut epithelial cell cycle arrest. Crit Care Med (2003) 1.83
A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol (2003) 1.81
Sepsis induces apoptosis and profound depletion of splenic interdigitating and follicular dendritic cells. J Immunol (2003) 1.76
Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun (2010) 1.76
Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol (2009) 1.75
Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. FASEB J (2007) 1.73
Effects of age on mortality and antibiotic efficacy in cecal ligation and puncture. Shock (2003) 1.73
Effects of aging on the immunopathologic response to sepsis. Crit Care Med (2009) 1.72
Cancer causes increased mortality and is associated with altered apoptosis in murine sepsis. Crit Care Med (2010) 1.68
Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock (2004) 1.68
Mesh reinforcement of pancreatic transection decreases incidence of pancreatic occlusion failure for left pancreatectomy: a single-blinded, randomized controlled trial. Ann Surg (2012) 1.58
High-dose exogenous iron following cecal ligation and puncture increases mortality rate in mice and is associated with an increase in gut epithelial and splenic apoptosis. Crit Care Med (2004) 1.54
Deletion of MyD88 markedly attenuates sepsis-induced T and B lymphocyte apoptosis but worsens survival. J Leukoc Biol (2008) 1.54
Akt decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol (2004) 1.54
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
Mechanisms of decreased intestinal epithelial proliferation and increased apoptosis in murine acute lung injury. Crit Care Med (2005) 1.49
A tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol (2005) 1.47
Isolation of right main and right sectional portal pedicles for liver resection without hepatotomy or inflow occlusion. J Am Coll Surg (2007) 1.46
Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer (2007) 1.46
Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res (2007) 1.44
Development of an immunoassay for the kidney-specific protein myo-inositol oxygenase, a potential biomarker of acute kidney injury. Clin Chem (2014) 1.43
TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol (2006) 1.41
Sepsis induces extensive autophagic vacuolization in hepatocytes: a clinical and laboratory-based study. Lab Invest (2009) 1.41
A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care (2012) 1.41
Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol (2006) 1.40
Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care (2013) 1.37
Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest (2002) 1.35
Laparoscopic gastric resection for gastrointestinal stromal tumors. Surg Endosc (2008) 1.34
Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure. J Am Coll Surg (2012) 1.33
Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock (2014) 1.30
Neutrophil depletion causes a fatal defect in murine pulmonary Staphylococcus aureus clearance. J Surg Res (2008) 1.30
Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res (2012) 1.30
Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy (2011) 1.29
Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg (2007) 1.28
Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock (2011) 1.26
CD25+ CD4+ regulatory T-cells in cancer. Immunol Res (2005) 1.26
Pneumonia after cecal ligation and puncture: a clinically relevant "two-hit" model of sepsis. Shock (2006) 1.26
Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother (2006) 1.26
Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect Immun (2010) 1.25
Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. Am J Physiol Regul Integr Comp Physiol (2005) 1.24
Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother (2009) 1.23
DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis. J Exp Med (2005) 1.22
The role of TCR engagement and activation-induced cell death in sepsis-induced T cell apoptosis. J Immunol (2006) 1.22
Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology (2011) 1.21
Bim siRNA decreases lymphocyte apoptosis and improves survival in sepsis. Shock (2008) 1.19
Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg (2007) 1.18
Epidermal growth factor treatment decreases mortality and is associated with improved gut integrity in sepsis. Shock (2008) 1.16
Parallels between cancer and infectious disease. N Engl J Med (2014) 1.16
Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol (2006) 1.15
CD4+ lymphocytes control gut epithelial apoptosis and mediate survival in sepsis. FASEB J (2009) 1.14
Streptococcus pneumoniae and Pseudomonas aeruginosa pneumonia induce distinct host responses. Crit Care Med (2010) 1.14
Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol (2004) 1.14
Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism. J Immunol (2010) 1.13
The σ2 receptor: a novel protein for the imaging and treatment of cancer. J Med Chem (2013) 1.13
Targeted delivery of siRNA to cell death proteins in sepsis. Shock (2009) 1.12
Decreased phospho-Akt signaling in a mouse model of total parenteral nutrition: a potential mechanism for the development of intestinal mucosal atrophy. Am J Physiol Gastrointest Liver Physiol (2010) 1.11
The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol Cancer (2010) 1.11
Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis (2012) 1.10
Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res (2009) 1.08
Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford) (2013) 1.08
Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer (2002) 1.07